Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
Stefanou DT, Bamias A, Episkopou H, Kyrtopoulos SA, Likka M, Kalampokas T, Photiou S, Gavalas N, Sfikakis PP, Dimopoulos MA, Souliotis VL.
Stefanou DT, et al. Among authors: dimopoulos ma.
PLoS One. 2015 Feb 6;10(2):e0117654. doi: 10.1371/journal.pone.0117654. eCollection 2015.
PLoS One. 2015.
PMID: 25659114
Free PMC article.
Clinical Trial.